EUCTR2018-001393-16-PT进行中（未招募）1 期
A Phase 2b, Multicenter, Randomized, Open-label, Two-Arm Study toEvaluate the Clinical Efficacy and Safety of OHB-607 Compared to StandardNeonatal Care for the Prevention of Bronchopulmonary Dysplasia, the MostCommon Cause of Chronic Lung Disease of Prematurity
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 338
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consents and/or assents must be signed and dated by the subject's parent(s) prior to any study-related procedures. The informed consent and any assents for underage parents must be approved by the IRB/IEC (in accordance with local regulations).
- •2. Written informed consents and/or assents must be signed and dated by the subject's birth mother prior to providing study-related information related to birth mother medical history, pregnancy and the birth of the subject. The informed consent and any assents for underage birth mothers must be approved by the IRB/IEC (in accordance with local regulations).
- •3. Subjects must be between 23 weeks +0 days and 27 weeks +6 days GA, inclusive.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 338
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Detectable major (or severe) congenital malformation identified before randomization.
- •2. Known or suspected chromosomal abnormality, genetic disorder, or syndrome, identified before randomization, according to the investigator's opinion.
- •3. Hypoglycemia at baseline (blood glucose <45 mg/dL or 2.5 mmol/L) which persists in spite of glucose supplementation, to exclude severe congenital abnormalities of glucose metabolism.
- •4. Clinically significant neurological disease identified before randomization according to cranial ultrasound (hemorrhages confined to the germinal matrix are allowed) and investigator's opinion.
- •5. Any other condition or therapy that, in the investigator's opinion, may pose a risk to the subject or interfere with the subject's potential compliance with this protocol or interfere with interpretation of results.
- •6. Current or planned participation in a clinical study of another investigational study treatment, device, or procedure (participation in non-interventional studies is permitted on a case-by-case basis).
- •7. The subject or subject's parent(s) is/are unable to comply with the protocol or is unlikely to be available for long-term follow-up as determined by the investigator.
- •8. Birth mother with active COVID-19 infection at birth or a history of severe COVID-19 infection (requiring intensive care hospitalization) during pregnancy.
- •Major (or severe) congenital malformations include structurally significant congenital heart disease, and structural abnormalities of the upper airway, lungs or chest wall. Congenital malformations that are suspected of being associated with chromosomal abnormalities, genetic syndromes, and neoplasia should be excluded, as well as abnormalities that may affect life expectancy, cardiopulmonary development, neurologic development, or
- •interpretation of study results.
- •Isolated minor dysmorphic anomalies that are unlikely to be exclusionary could include post-axial polydactyly, ankyloglossia, accessory nipples, preauricular pits, single or horizontal palmar crease,
- •clinodactyly, and single umbilical artery. However, the presence of multiple minor anomalies in the same infant may be exclusionary.
- •Uncomplicated infantile hemangiomas are unlikely to be exclusionary.
- •However, subjects with infantile hemangiomas that may be associated with potential for disfigurement, life-threatening complications, functional impairment, ulceration, or underlying abnormalities should be excluded.
- •Inclusion/exclusion will ultimately be determined by the investigator, based on assessment of the clinical presentation of each candidate subject and the likelihood that physical finding(s) are associated with a condition that impacts health and development.
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the safety and efficacy of an experimental drug for chronic lung disease against normally prescribed care in extremely premature babiesChronic Lung DiseaseMedDRA version: 21.1Level: LLTClassification code 10066204Term: Chronic lung disease of prematuritySystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-001393-16-DEOHB Neonatology Ltd338
进行中（未招募）
1 期
A study evaluating the safety and efficacy of an experimental drug for chronic lung disease against normally prescribed care in extremely premature babiesChronic Lung DiseaseMedDRA version: 21.1Level: LLTClassification code 10066204Term: Chronic lung disease of prematuritySystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-001393-16-NLOHB Neonatology Ltd338
尚未招募
2 期
A Phase 2b, Multicenter, Randomized, Open-label, Two-Arm Study to Evaluate the Clinical Efficacy and Safety of OHB-607 Compared to Standard Neonatal Care for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease of Prematuritybronchopulmonary dysplasiaChronic lung disease10028971NL-OMON52648OHB Neonatology Ltd12
进行中（未招募）
1 期
A study evaluating the safety and efficacy of an experimental drug for chronic lung disease against normally prescribed care in extremely premature babiesEUCTR2018-001393-16-FIOHB Neonatology Ltd338
进行中（未招募）
1 期
A study evaluating the safety and efficacy of an experimental drug for chronic lung disease against normally prescribed care in extremely premature babiesChronic Lung DiseaseMedDRA version: 21.1Level: LLTClassification code 10066204Term: Chronic lung disease of prematuritySystem Organ Class: 100000004855EUCTR2018-001393-16-SEOHB Neonatology Ltd338